卵巢癌患者CD8^+ T细胞中调节性T细胞相关分子标志物的表达率及临床意义

A study on expression and clinical significance of Treg markers in CD8^+ T cells in ovarian cancer patients

目的 :检测卵巢癌患者组织及外周血CD8^+T细胞中调节性T细胞(regulatory T cells,Treg)相关分子标志物的表达率,探讨其在卵巢癌发生发展中的临床意义。方法:用流式细胞术检测31例卵巢癌患者、31例卵巢良性肿瘤患者和31例健康对照者的外周血,以及14例卵巢癌组织和12例卵巢良性肿瘤组织CD8^+T细胞中Foxp3、CD25、CD28、CTLA-4及GITR的表达率。结果:Foxp3和CTLA-4在卵巢癌组织CD8^+T细胞中的表达率显著高于卵巢良性肿瘤组织(P<0.05);CD28在卵巢癌组织CD8^+T细胞中的表达率显著低于卵巢良性肿瘤组织(P<0.05)。卵巢癌患者外周血CD8+T细胞中Foxp3、CD25、CTLA-4的表达率显著高于卵巢良性肿瘤患者和健康对照者(P<0.05),CD28的表达率显著低于卵巢良性肿瘤患者和健康对照者(P<0.05)。结论:卵巢癌组织及外周血CD8^+Treg所占的比例显著高于卵巢良性肿瘤组及健康对照组,且CD8^+T细胞中Foxp3的表达率可能对了解卵巢癌进展状况有一定帮助。

Objective：To investigate the expression and clinical significance of Treg markers in CD8^＋T cells from peripheral blood and tumor tissues of ovarian cancer patients. Methods： Flow cytometry was used to detect the percentage of Foxp3, CD25, CD28,CTLA-4 and GITR in CD8^＋T cells in tissues from 12 benign ovarian tumor patients, 14 ovarian cancer patients, in peripheral blood from 31 patients with ovarian cancer, 31 patients with benign ovarian tumor and 31 healthy volunteers. Results： Flow cytometry revealed that the expressions of Foxp3 and CTLA-4 in CD8^＋T cells of ovarian cancer tissues were higher than those of benign ovarian tumor tissues（P〈0.05）; The expression of CD28 in CD8^＋T cells of ovarian cancer tissues was significantly lower than that of benign ovarian tumor tissues（P〈0.01）; The expressions of Foxp3, CD25 and CTLA-4 gated on CD8^＋T cells in peripheral blood of ovarian cancer patients were significantly higher than those of patients with benign ovarian tumor and healthy control subjects（P〈0.05）, the expression of CD28 gated on CD8^＋T cells in peripheral blood of ovarian cancer patients was significantly lower than that of patients with benign ovarian tumor and healthy control subjects（P〈0.05）. Conclusion： Frequency of CD8^＋Treg in ovarian cancer patients was higher than benign ovarian tumor patients and healthy controls. The expression of Foxp3 in CD8^＋T cells in peripheral blood of ovarian cancer patients correlated with tumor stage, suggesting Foxp3 could be used as an important indicator of ovarian cancer progression.